10-Q: Coherus BioSciences Reports Strong Q1 2024 Results on Sale of Ophthalmology Franchise, Focus Shifts to Oncology Pipeline

Coherus BioSciences reported a significant net income boost in Q1 2024, driven by the strategic sale of its CIMERLI ophthalmology franchise to Sandoz for $170 million, allowing the company to pay down debt and intensify its focus on its oncology portfolio.

Summary

• Coherus BioSciences, Inc. reported financial results for the first quarter ended March 31, 2024.
• The company completed the sale of its CIMERLI ophthalmology franchise to Sandoz for $170 million plus $17.8 million for inventory and prepaid manufacturing assets on March 1, 2024, resulting in a net gain of $153.6 million.
• The proceeds were used to pay down $175 million of the company's term loan debt in April 2024.
• Total net revenue for Q1 2024 was $77.1 million, up from $32.4 million in Q1 2023, driven by sales of UDENYCA, CIMERLI (prior to divestiture), YUSIMRY, and the newly launched LOQTORZI.
• Net income for Q1 2024 was $102.9 million, compared to a net loss of $75.7 million in Q1 2023.
• Research and development expenses decreased to $28.5 million in Q1 2024 from $34.2 million in Q1 2023.
• Selling, general, and administrative expenses increased to $56.5 million in Q1 2024 from $49.2 million in Q1 2023, primarily due to a $6.8 million net impairment charge related to an out-licensed asset and an increase of $5.6 million in professional service fees.
• The company terminated its TIGIT program with Junshi Biosciences to focus on more promising pipeline candidates.
• Coherus is focusing on its oncology portfolio, including LOQTORZI, casdozokitug (CHS-388), CHS-114, and CHS-1000.
• On May 8, 2024, Coherus entered into a new senior secured term loan facility of up to $38.7 million and a revenue participation right purchase and sale agreement for $37.5 million, using the proceeds to fully repay the existing $75 million outstanding on the 2027 Term Loans.

Sentiment

Score: 8

Explanation: The document reflects a positive sentiment due to the successful sale of the CIMERLI franchise, significant revenue growth, debt reduction, and a strategic focus on the oncology pipeline. However, the increasingly competitive landscape and inherent risks in drug development warrant a slightly cautious outlook.

Positives

• Significant net income in Q1 2024 driven by the sale of the CIMERLI franchise.
• Successful debt reduction through proceeds from the CIMERLI sale.
• Increased revenue from UDENYCA due to new presentations and higher demand.
• Launch of LOQTORZI in the U.S. market.
• Continued sales of YUSIMRY following its launch in July 2023.
• Focus on promising oncology pipeline candidates.
• Strategic portfolio prioritization to allocate resources effectively.
• New financing secured to fully repay existing term loan debt.

Negatives

• Cessation of CIMERLI revenue following its divestiture.
• Increase in selling, general, and administrative expenses.
• Net impairment charge of $6.8 million related to the termination of the Novartis Institutes out-license.
• Termination of the TIGIT program with Junshi Biosciences, although aimed at focusing resources.
• Continued competitive pressure in the biosimilar market.

Risks

• Uncertainty in achieving profitability in future periods.
• Dependence on market acceptance and adoption of products by physicians, healthcare providers, and patients.
• Reliance on third parties for manufacturing and clinical trials.
• Intense competition in the biosimilar and immuno-oncology markets.
• Potential for product candidates to cause undesirable side effects.
• Risk of intellectual property infringement claims.
• Challenges in obtaining and maintaining regulatory approvals.
• Impact of healthcare reform measures and pricing pressures.
• Dependence on key personnel and ability to attract and retain talent.
• Volatility in the market price of the company's common stock.

Future Outlook

Coherus expects lower net revenue in the remainder of 2024 compared to 2023 due to the divestiture of CIMERLI, but anticipates this to be partially offset by market share growth of UDENYCA and continued sales of LOQTORZI and YUSIMRY. The company also projects lower research and development expenses in 2024 due to cost containment initiatives and termination of the TIGIT program, and lower selling, general, and administrative expenses due to the Sale Transaction, reduced headcount, and decreased commercial costs.

Management Comments

• The company is focusing on its oncology portfolio and the launch of LOQTORZI.
• Management is prioritizing the most promising and competitively positioned product candidates.
• The company is committed to winding down work with Junshi Biosciences on the TIGIT program while supporting patients in the current study.

Industry Context

The announcement reflects the broader industry trend of strategic divestitures and refocusing on core therapeutic areas. Coherus' shift to oncology aligns with the growing importance of immuno-oncology in cancer treatment. The biosimilar market continues to be competitive, with multiple players vying for market share.

Comparison to Industry Standards

• Coherus' UDENYCA competes with Amgen's Neulasta and other pegfilgrastim biosimilars from Viatris, Sandoz, Pfizer, Spectrum, Amneal, and Fresenius. UDENYCA's multiple presentations provide a competitive advantage.
• YUSIMRY competes with AbbVie's Humira and other adalimumab biosimilars from Amgen, Sandoz, Samsung Bioepis, Pfizer, Boehringer Ingelheim, Viatris/Biocon, Alvotech, and Fresenius. The market is highly competitive with multiple biosimilars launched.
• LOQTORZI competes with other anti-PD-1/PD-L1 antibodies like Merck's Keytruda, BMS's Opdivo, Genentech's Tecentriq, AstraZeneca's Imfinzi, EMD Serono/Pfizer's Bavencio, Regeneron's Libtayo, GlaxoSmithKline's Jemperli, and BeiGene's TEVIMBRA. LOQTORZI is the only FDA-approved immunotherapy for nasopharyngeal carcinoma.
• Casdozokitug faces competition from programs in development specifically targeting CCR8, including those by Bristol-Myers Squibb Company, Gilead/Jounce, Shionogi, AbbVie, Bayer, F. Hoffmann-La Roche Ltd, Amgen, LaNova and Immunophage.

Legal Proceedings

• The Company is a party to various legal proceedings and claims that arise in the ordinary, routine course of business and that have not been fully resolved.
• The Company established an accrual as of March 31, 2024 that represented its estimated liability to resolve the matter in connection with a demand letter received from Zinc Health Services, LLC in late April of 2022.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to debt reduction, focus on oncology, and revenue growth. However, stock price volatility and dilution risks remain.
• Employees: Potential impact from restructuring and changes in company focus. The document mentions a reduction in force in Q1 2023.
• Customers: Continued availability of UDENYCA, YUSIMRY, and LOQTORZI. Potential for new treatment options in oncology.
• Suppliers: Changes in demand for manufacturing services depending on product success and pipeline development.
• Creditors: Reduced debt levels improve the company's financial position. The new 2029 Term Loan and Revenue Purchase and Sale Agreement introduce new creditors and obligations.

Next Steps

• Continue commercialization efforts for UDENYCA, LOQTORZI, and YUSIMRY.
• Advance the clinical development of casdozokitug, CHS-114, and CHS-1000.
• Wind down the TIGIT program with Junshi Biosciences.
• Monitor the impact of the IRA on the pharmaceutical industry and adapt accordingly.
• Continue to evaluate strategic opportunities and manage resources effectively.

Key Dates

Keywords

Coherus BioSciences, Oncology, Immunotherapy, Biosimilar, UDENYCA, LOQTORZI, YUSIMRY, CIMERLI, Pegfilgrastim, Adalimumab, Ranibizumab, Nasopharyngeal Carcinoma, FDA Approval, Clinical Trials, Drug Development, Commercialization, Sandoz, Junshi Biosciences, Surface Acquisition, Casdozokitug, CHS-114, CHS-1000, Financial Results, Debt Reduction, Capital Raise